- Home
- BWLP vs IMCR Comparison
BWLP vs IMCR Comparison
Compare BWLP & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BWLP | IMCR |
|---|---|---|
| Founded | 1935 | 2008 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BWLP | IMCR |
|---|---|---|
| Price | $13.07 | $34.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | ★ 420.1K | 270.5K |
| Earning Date | 12-02-2025 | 11-06-2025 |
| Dividend Yield | ★ 10.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,693,482,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.28 |
| Revenue Next Year | $8.16 | $10.66 |
| P/E Ratio | $11.78 | ★ N/A |
| Revenue Growth | 2.54 | ★ 28.11 |
| 52 Week Low | $7.86 | $23.15 |
| 52 Week High | $16.60 | $40.72 |
Technical Indicators
Market Signals| Indicator | BWLP | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 42.51 |
| Support Level | $12.31 | $34.00 |
| Resistance Level | $13.14 | $36.64 |
| Average True Range (ATR) | 0.22 | 1.46 |
| MACD | 0.11 | -0.28 |
| Stochastic Oscillator | 93.48 | 18.30 |
Price Performance
Historical ComparisonAbout BWLP BW LPG Limited
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.